Thermo Fisher Scientific and NextGen Sciences Announce Collaboration
News Jun 18, 2009
Thermo Fisher Scientific Inc. has announced a collaboration between its Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center and NextGen Sciences, the biomarker specialists providing discovery, assay development and testing services.
Under the collaboration arrangement, the BRIMS Center will work with NextGen Sciences to apply new technologies to NextGen Sciences’ biomarkerexpress™ platform, a suite of biomarker services for developing, validating and applying targeted SRM assays for peptides and proteins in biofluids and tissues.
The collaboration will include providing NextGen Sciences with access to Thermo Scientific mass spectrometry technology, which the company will add to its existing Thermo Scientific-based workflow.
The biomarkerexpress™ workflow presently includes the following technologies and software for the biomarker discovery phase: Thermo Scientific LTQ Orbitrap XL mass spectrometer, Thermo Scientific SIEVE software for label-free differential analysis, and Thermo Scientific Proteome Discoverer software.
The Thermo Scientific TSQ Quantum Ultra triple stage quadrupole mass spectrometer and Thermo Scientific Pinpoint software are employed for development and testing of panels of potential new biomarkers.
“We were diligent in our search for best-in-class instrumentation. While we were putting in place the infrastructure for our biomarker services it was important that we looked for reliable and accurate instruments, and Thermo Scientific technology was found to be just that,” said Dr. Michael Pisano, CEO of NextGen Sciences.
“In concert with our expertise at NextGen Sciences, Thermo Scientific technology delivers the highest quality results to our customers. The combination of Orbitrap™ technology and triple quad capability enables NextGen Sciences to go from discovery or named proteins to a single or multi-protein assay in a very short timeframe.”
NextGen Sciences has been working closely with BRIMS over the past year to develop an assay to verify osteoarthritis (OA) biomarker candidates in synovial fluid. The putative biomarkers were discovered in previous work performed at Harvard Medical School and Case Western Reserve University. The OA biomarker panel is currently being tested at NextGen Sciences on a 1,000-patient sample cohort provided by Harvard Medical School.